HC Wainwright Has Positive Outlook of OLMA FY2026 Earnings

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Stock analysts at HC Wainwright increased their FY2026 earnings per share estimates for Olema Pharmaceuticals in a research report issued to clients and investors on Friday, May 22nd. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($2.24) for the year, up from their prior forecast of ($2.25). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.16) per share.

OLMA has been the subject of a number of other reports. Stifel Nicolaus initiated coverage on Olema Pharmaceuticals in a research report on Wednesday, February 11th. They issued a “buy” rating and a $48.00 price objective for the company. Jefferies Financial Group initiated coverage on Olema Pharmaceuticals in a research report on Thursday, March 19th. They issued a “buy” rating and a $40.00 price objective for the company. Oppenheimer reiterated an “outperform” rating on shares of Olema Pharmaceuticals in a research report on Monday, March 9th. TD Cowen restated a “buy” rating on shares of Olema Pharmaceuticals in a report on Monday, March 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a report on Tuesday, April 21st. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $44.10.

Olema Pharmaceuticals Price Performance

Shares of OLMA stock opened at $13.55 on Wednesday. The stock has a 50-day moving average price of $14.86 and a 200 day moving average price of $20.77. The company has a quick ratio of 10.88, a current ratio of 10.88 and a debt-to-equity ratio of 0.01. The firm has a market cap of $1.18 billion, a price-to-earnings ratio of -6.71 and a beta of 2.05. Olema Pharmaceuticals has a 12 month low of $3.89 and a 12 month high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.52) EPS for the quarter, hitting analysts’ consensus estimates of ($0.52).

Insider Buying and Selling at Olema Pharmaceuticals

In other news, insider Shawnte Mitchell sold 25,000 shares of Olema Pharmaceuticals stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $24.25, for a total transaction of $606,250.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 12.56% of the stock is owned by company insiders.

Hedge Funds Weigh In On Olema Pharmaceuticals

Institutional investors have recently modified their holdings of the business. EverSource Wealth Advisors LLC lifted its holdings in shares of Olema Pharmaceuticals by 9,476.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock valued at $31,000 after purchasing an additional 1,232 shares in the last quarter. Torren Management LLC bought a new position in shares of Olema Pharmaceuticals during the 4th quarter valued at about $44,000. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in shares of Olema Pharmaceuticals during the 4th quarter valued at about $88,000. Nisa Investment Advisors LLC lifted its holdings in shares of Olema Pharmaceuticals by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock valued at $94,000 after purchasing an additional 477 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Olema Pharmaceuticals by 44.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,822 shares of the company’s stock valued at $96,000 after purchasing an additional 1,169 shares in the last quarter. Institutional investors own 91.78% of the company’s stock.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.